Q1 2026 Abeona Therapeutics Inc Earnings Call Transcript

May 13, 2026 / 12:30 PM GMT

Release Date Price: $5.71 (+0.53%)

Transcript 10-Q8-K

Key Points

Positve

Abeona Therapeutics Inc (ABEO) reported strong revenue growth with $8.7 million in net revenue for Q1 2026, driven by the commercial launch of ZevaSkin.
The company successfully activated six qualified treatment centers (QTCs) and treated five commercial patients, with additional patients scheduled for treatment.
Positive feedback from QTCs and patients indicates strong demand and successful treatment experiences with ZevaSkin.
Abeona Therapeutics Inc (ABEO) has secured 95% commercial coverage for ZevaSkin, indicating broad payer acceptance.
The company announced the in-licensing of a novel cell therapy asset targeting advanced prostate cancer, expanding its R&D pipeline.

Negative

The insurance approval process for ZevaSkin is lengthy, particularly for out-of-state Medicaid patients, which could delay treatments.
Operating expenses increased significantly, with selling, general, and administrative expenses rising to $19.5 million, reflecting continued investment in commercial infrastructure.
The company reported a net loss of $17.1 million for the quarter, primarily due to increased commercial investment and licensing transactions.
There is uncertainty regarding the exact number of patients that will be treated in the upcoming quarters, making it difficult to predict revenue accurately.
The transition of certain manufacturing costs to inventory and engineering runs is no longer considered R&D, which may impact future financial reporting.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ABEO.OQ - Abeona Therapeutics Inc
Q1 2026 Abeona Therapeutics Inc Earnings Call
May 13, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, ladies and gentlemen, and welcome to the Abiona Therapeutics First Quarter 2026 Earnings Conference Call.

At this time, all participants are on a listen-only mode. And a question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press *0 on your telephone keypad.

And please note, this conference is being recorded.

I will now turn the conference over to your host, Mr. Joe Vazzano, Chief Financial Officer at Abiona Therapeutics. Sir, the floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.